Literature DB >> 23319007

[Lymph node pathology - an update].

S Hartmann1, M L Hansmann.   

Abstract

Immune suppression is a risk factor for malignant lymphoma development. Progress in medical science has increased the numbers of immunosuppressed patients due to organ transplantations or successful treatment of autoimmune diseases. Different forms of immune suppression and the respective lymphoma entities are discussed in this article. Another issue treated are gray zone lymphomas between Hodgkin's lymphoma and diffuse large B cell lymphoma. This category not only represents a diagnostic challenge but also represents more a true biological continuum.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23319007     DOI： 10.1007/s00292-012-1706-5

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  79 in total

1.  Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.

Authors:  S Joos; M Küpper; S Ohl; F von Bonin; G Mechtersheimer; M Bentz; P Marynen; P Möller; M Pfreundschuh; L Trümper; P Lichter
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

2.  Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Pei Lin; Timothy J Dickason; Luis E Fayad; Patrick A Lennon; Peter Hu; Mar Garcia; Mark J Routbort; Roberto Miranda; Xumei Wang; Wei Qiao; L Jeffrey Medeiros
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

3.  Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells.

Authors:  Daniela Baus; Edith Pfitzner
Journal:  Int J Cancer       Date:  2006-03-15       Impact factor: 7.396

4.  FOXP3(+) regulatory and TIA-1(+) cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma.

Authors:  Junichi Kiyasu; Ryosuke Aoki; Paula Yurie Tanaka; Luis Fernando Pracchia; Edenilson Eduardo Calore; Nilda Maria Perez; Yoshizo Kimura; Daisuke Niino; Yasuo Sugita; Ryoichi Takayanagi; Yasunobu Abe; Masao Matsuoka; Koichi Ohshima
Journal:  Pathol Int       Date:  2012-02       Impact factor: 2.534

5.  Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.

Authors:  D M Knowles; E Cesarman; A Chadburn; G Frizzera; J Chen; E A Rose; R E Michler
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

6.  Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma.

Authors:  Alexandar Tzankov; Matthias S Matter; Stephan Dirnhofer
Journal:  Pathobiology       Date:  2011-01-24       Impact factor: 4.342

7.  Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Franziska C Eberle; Jaime Rodriguez-Canales; Lai Wei; Jeffrey C Hanson; J Keith Killian; Hong-Wei Sun; Lisa G Adams; Stephen M Hewitt; Wyndham H Wilson; Stefania Pittaluga; Paul S Meltzer; Louis M Staudt; Michael R Emmert-Buck; Elaine S Jaffe
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

8.  Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.

Authors:  Ramón Bosch Príncep; Marylène Lejeune; Maria Teresa Salvadó Usach; Joaquín Jaén Martínez; Lluis E Pons Ferré; Tomás Alvaro Naranjo
Journal:  Ann Hematol       Date:  2005-05-05       Impact factor: 3.673

9.  Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.

Authors:  Margaret L Gulley; Lode J Swinnen; Kerry T Plaisance; Carrie Schnell; Thomas M Grogan; Barbara G Schneider
Journal:  Transplantation       Date:  2003-09-27       Impact factor: 4.939

10.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  1 in total

Review 1.  [Malignant lymphomas in children and adolescents. Practical knowledge for diagnosis].

Authors:  I Oschlies; W Klapper
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.